|1.||Rosenberg, Steven A: 15 articles (03/2015 - 05/2002)|
|2.||Ribas, Antoni: 11 articles (05/2013 - 03/2003)|
|3.||Romero, Pedro: 10 articles (09/2014 - 07/2002)|
|4.||Economou, James S: 10 articles (05/2013 - 03/2003)|
|5.||Speiser, Daniel E: 8 articles (09/2014 - 02/2003)|
|6.||Stevanovic, Stefan: 8 articles (05/2009 - 05/2002)|
|7.||Rivoltini, Licia: 7 articles (05/2013 - 04/2003)|
|8.||Parmiani, Giorgio: 7 articles (05/2013 - 04/2003)|
|9.||Price, David A: 7 articles (10/2012 - 04/2004)|
|10.||Gostick, Emma: 7 articles (10/2012 - 04/2004)|
10/15/2002 - "Establishment of an HLA-A*0201 human papillomavirus type 16 tumor model to determine the efficacy of vaccination strategies in HLA-A*0201 transgenic mice."
11/01/2007 - "In conclusion, we have identified a new CTL HLA-A*0201 restricted hTERT epitope, which is now, included in an ongoing phase 2 vaccine trial of patients with disseminated cancer."
12/01/2015 - "Several analogs containing the auxiliary HLA-A*0201 anchor residues were able to stably bind to HLA-A*0201 and enhance CTL responses compared with the native sequence; two of them showed increased anti-tumor effects during the adoptive immunotherapy in vivo. "
01/01/2014 - "C57BL/6J, BALB/c, and HLA-A*0201 transgenic mice immunized with yeast expressing X-S-Core showed T cell responses to X, S and Core when evaluated by lymphocyte proliferation assay, ELISpot, intracellular cytokine staining (ICS), or tumor challenge assays. "
11/01/2012 - "The CTL clone against p675 elicited a significant cancer cell inhibition effect HLA-A*0201 restrictly. "
|2.||Melanoma (Melanoma, Malignant)
10/01/2006 - "Between March 1999 and May 2000, 18 HLA-A*0201(+) patients with metastatic melanoma were enrolled in a phase I trial using a dendritic cell (DC) vaccine generated by culturing CD34(+) hematopoietic progenitors. "
11/01/2005 - "We report in this study on vaccination efforts in 95 HLA-A*0201 patients at high risk for recurrence of malignant melanoma who received prolonged immunization with the "anchor-modified" synthetic peptide, gp100209-217(210M). "
09/01/2005 - "Twenty-two HLA A*0201 patients with stage IV melanoma were enrolled in a phase 1 safety and feasibility trial using a composite dendritic cell (DC) vaccine generated by culturing CD34 hematopoietic progenitors and activated with IFN-alpha. "
09/01/2004 - "In an open-label phase 2 trial, 10(7) autologous ex vivo generated DCs pulsed with the HLA-A*0201 immunodominant peptide MART-1(27-35) were administered to 10 subjects with stage II-IV melanoma. "
03/01/2003 - "In this study we compared several protocols for in vitro induction of cytotoxic T lymphocytes (CTL) from naïve HLA-A*0201(+) peripheral blood mononuclear cells (PBMC) against allogeneic melanoma cells. "
06/01/1998 - "A comparison of viral sequences derived from 10 HLA-A*0201-positive individuals to sequences obtained from 11 HLA-A*0201-negative individuals demonstrated only weak evidence for immune selective pressure and thus question the in vivo efficacy of immunodominant CTL responses present during chronic HIV-1 infection."
11/01/2004 - "The construct with the highest immunogenicity for each epitope was tested for protective efficacy in a preclinical model of infection using HTLV-1 Tax recombinant vaccinia virus and HLA-A*0201 transgenic mice. "
09/01/2003 - "The low efficiency was epitope-specific since infection of DC with rVV encoding a gp100 construct containing the modified gp100:209-217 (210M) (g209-2M) epitope characterized by high binding affinity for HLA-A*0201 restored efficient Ag presentation. "
01/15/2001 - "This epitope is targeted by 75% of HLA-A*0201-positive adults, and the magnitude of this A*0201-SL9 response shows a strong negative association with viral load in progressive infection. "
06/01/1998 - "Lack of strong immune selection pressure by the immunodominant, HLA-A*0201-restricted cytotoxic T lymphocyte response in chronic human immunodeficiency virus-1 infection."
|4.||T-Cell Leukemia (Leukemia, T Cell)
10/01/2001 - "Conserved CDR3 regions in T-cell receptor (TCR) CD8(+) T cells that recognize the Tax11-19/HLA-A*0201 complex in a subject infected with human T-cell leukemia virus type 1: relationship of T-cell fine specificity and major histocompatibility complex/peptide/TCR crystal structure."
05/01/2006 - "A squirrel monkey model of human T-cell leukemia virus type 1 (HTLV-1) infection was used to evaluate the immunogenicity and protective efficacy of a chimeric peptide vaccine composed of a B-cell epitope from the envelope region (aa 175-218) and three HLA-A*0201-restricted cytotoxic T-lymphocyte epitopes derived from Tax protein (Tri-Tax). "
10/01/2013 - "HLA-A 0201/NY-ESO-1157-165 redirected T-cells were generated, expanded and tested for CAR expression, cytokine release, in vitro cytolysis and protection against xenografted HLA-A 0201/NY-ESO-1157-165-positive multiple myeloma cells. "
11/01/2013 - "Identification of human leucocyte antigen (HLA)-A*0201-restricted cytotoxic T lymphocyte epitopes derived from HLA-DOβ as a novel target for multiple myeloma."
|4.||T-Lymphocyte Epitopes (Epitopes, T Lymphocyte)
|5.||HLA-A2 Antigen (HLA A2 Antigen)
|6.||Interferon-gamma (Interferon, gamma)
|8.||gp100 Melanoma Antigen
|9.||B-Lymphocyte Epitopes (B-Cell Epitope)
|10.||tax Gene Products (tax Gene Product)
|4.||Stem Cell Transplantation